[Skip to Content]
[Skip to Content Landing]
Views 2,572
Citations 0
Research Letter
August 5, 2019

Industry Payments to Physician Directors of National Cancer Institute–Designated Cancer Centers, 2015-2017

Author Affiliations
  • 1Department of Pathology, University of California, San Diego, La Jolla
  • 2Thetford, Vermont
JAMA Intern Med. Published online August 5, 2019. doi:10.1001/jamainternmed.2019.3098

National Cancer Institute (NCI)–designated cancer centers shape cancer care in the United States and are supported by substantial public funds (in fiscal year 2018, $330 million in core funding for 70 cancer centers).1 Cancer care is also shaped by industry, because developing new cancer therapeutics represents a major market opportunity. Industry payments to academic physicians risk blurring the line between innovation and the evaluation of new therapies. We used Open Payments data from the Centers for Medicare & Medicaid Services (CMS) to examine industry payments made to physician directors of NCI-designated cancer centers.

Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Not all submitted comments are published. Please see our commenting policy for details.

Limit 140 characters
Limit 3600 characters or approximately 600 words
    ×